0 0 0.000447174931636994 0.00039954130582551 0.00211705003606246 0.000555206749653611 -5.70773294035938E-05 -5.70773294035938E-05
Sign Up Today X
Thanks for submitting the form.
Stockreport

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate [Seeking Alpha]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Seeking Alpha
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancing Regeneron's oncology presence. Regeneron benefits financially from Dupixent sales and a strong balance sheet, indicating robust financial health and investment in pipeline development. I recommend buying Regeneron shares, due to diversified product strength, pipeline potential, and manageable risks despite market challenges. Regeneron: Sailing the Eye of the Market Storm with Eylea HD I last covered Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) in August, right after it received FDA approval for its high-dose Eylea (Eylea HD), a blockbuster drug for the treatment of wet age-related macular degeneration [AMD]. My recommendation was "buy," and the stock, up 16% since that call, is essentially even with the broader market. For some more background: Eylea is one of a few vascular endothelial growth factor (VEGF) inhibitors utilized for wet AMD. These therapies are typically utilized fi [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate [Seeking Alpha]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Seeking Alpha
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancing Regeneron's oncology presence. Regeneron benefits financially from Dupixent sales and a strong balance sheet, indicating robust financial health and investment in pipeline development. I recommend buying Regeneron shares, due to diversified product strength, pipeline potential, and manageable risks despite market challenges. Regeneron: Sailing the Eye of the Market Storm with Eylea HD I last covered Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) in August, right after it received FDA approval for its high-dose Eylea (Eylea HD), a blockbuster drug for the treatment of wet age-related macular degeneration [AMD]. My recommendation was "buy," and the stock, up 16% since that call, is essentially even with the broader market. For some more background: Eylea is one of a few vascular endothelial growth factor (VEGF) inhibitors utilized for wet AMD. These therapies are typically utilized fi [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS